Erasca (ERAS) Stock Price, Quote, News & History | Benzinga

Erasca Inc (ERAS) Stock Price, Quote, News & History

ERASNASDAQ

Trade with Public

Trade with Public

$17.63

0.553.22%

At close: Aug 21, 5:00 PM EST

$17.64

0.010.06%

After Hours: Aug 21, 4:00 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$17.28

Close

$17.63

Volume / Avg.

2.45M / 4.86M

Day Range

$17.21 - $17.84

52 Wk Range

1.33 - 24.28

Market Cap

$6.17B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

9.48%

Days to Cover

7.27

Recent Erasca, Inc. News

Erasca Unveils Updated Cancer Candidate Progress, Maps Path Toward Pivotal Cancer Trials

Erasca reported updated Phase 1 ERAS-0015 data, outlined pivotal trial plans and priced an upsized $550 million stock offering.

Vandana Singh

This KeyBanc Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

Top analysts upgrade MUR, UNH, ESNT, and ERAS stocks. For more rating changes, see analyst ratings page. See what analysts think of UNH stock.

Avi Kapoor

Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday

Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries, Qfin Holdings, Editas Medicine, and others.

Avi Kapoor

Crude Oil Gains Over 3%; General Motors Earnings Top Views

US stocks down, NASDAQ falls over 1% on Tuesday. Dow up 0.20%, NASDAQ down 1.24%, S&P 500 down 0.65%. GM reports better-than-expected Q1 results.

Avi Kapoor

CommVault, Kforce, AxoGen And Other Big Stocks Moving Higher On Tuesday

U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimates. Other gainers include Kforce, Omnicell, and AxoGen.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-98.02M

Investing Cash Flow (TTM)

-173.92M

Financing Cash Flow (TTM)

248.34M

Free Cash Flow (TTM)

-252.08M

Capital Expenditure (TTM)

-154.06M

Net Change in Cash (TTM)

-23.60M

Analyst Trends and Forecast

1

May

1

Jun

2

Jul

2

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.7

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$5.95B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

16.50

Earnings Yield % (TTM)

-5.57%

Earnings Yield % (FWD)

-5.86%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.03

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$42.54M

Debt to Equity

0.12

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$17.28

Close

$17.63

Volume / Avg.

2.45M / 4.86M

Day Range

$17.21 - $17.84

52 Wk Range

1.33 - 24.28

Market Cap

$6.17B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

9.48%

Days to Cover

7.27

About

Sector

Health Care

Industry

Biotechnology

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnosti...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Erasca (ERAS) stock?

A

You can purchase shares of Erasca (NASDAQ:ERAS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Erasca (ERAS) competitors?

A

Other companies in Erasca’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Erasca (ERAS) stock?

A

Erasca has a consensus price target of $14.21.

Q

What is the current price for Erasca (ERAS)?

A

The stock price for Erasca (NASDAQ: ERAS) is $17.64 last updated August 21, 2026 at 4:00 PM EDT.

Q

Does Erasca (ERAS) pay a dividend?

A

There are no upcoming dividends for Erasca.

Q

When is Erasca (NASDAQ:ERAS) reporting earnings?

A

Erasca does not have any upcoming earnings scheduled.

Q

Is Erasca (ERAS) going to split?

A

There is no upcoming split for Erasca.

Q

What sector and industry does Erasca (ERAS) operate in?

A

Erasca is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.